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Objectives: Comparative evaluation of the cost effectiveness of treatment of 
patients with acute craniocerebral injury (CCI) efficiency using two therapy schemes 
in Ukraine. MethOds: “The cost-efficiency” method was used to carrying out the 
research. Analysis was based on the results of opened randomized trial on the 
efficacy of L-Lysine Aescinat in patients with craniocerebral injury, carried out 
in the department of anesthesiology and intensive care at Regional hospital in 
Dnepropetrovsk. The clinical trial involved 38 patients randomized to main and 
control group (each group contained 19 patients). Standard therapy (fentanyl, 
diazepam, tramadol, adrenaline, furosemide, mannitol) and injections of L-Lysine 
Aescinat were administrated in main group; only standard therapy was adminis-
trated in the control group. Treatment of patients was carried out during 7 days. 
Direct costs were taken into account for therapy course expenditures schemes 
studying. Drugs prices were taken from Morion`s information system (May, 2015). 
As an indicator of the effectiveness after treatment were considered the follow-
ing: decreasing of intracranial hypertension, degree of brain perifocal edema and 
degree of conscious disturbance (Glasgow Coma Scale). Results: The treatment 
efficiency in main group patients was 73,68 % and 15.79 % in controls. Treatment 
costs were € 55,86 and € 31,84 correspondingly. “The cost-efficiency” analysis 
demonstrated that CER in main group was € 75,81and CER in control group was € 
201,65. cOnclusiOns: The “cost-efficiency” analysis showed the use of L-Lysine 
Aescinat in combination with standard therapy to be more effective and less expen-
sive for treatment of 1 patient with craniocerebral injury in Ukraine The obtained 
results of pharmacoeconomic analysis will allow to optimize the costs of disease 
treatment by a state, insurance companies and patients.
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Objectives: Myelofibrosis (MF) is a rare and life-threatening myeloproliferative 
disorder characterized by progressive scarring of the bone marrow and a number 
of severely debilitating symptoms. The objective of this analysis was to estimate 
cost-effectiveness of ruxolitinib (RUX) in a treatment of MF patients compared with 
best available therapy (BAT) in Finland. MethOds: Efficacy data from RUX pivotal 
trial COMFORT-II was used as the most relevant clinical evidence of RUX versus BAT. 
A survival-based decision model with health states On-Treatment, Off-Treatment 
and Dead was constructed. Transitions between the health states were determined 
by overall survival (OS) and treatment discontinuation collected in COMFORT-II. 
Treatment discontinuation was used a proxy for progression. The model was calcu-
lated as a cohort expected value analysis with each health state having associated 
costs and utilities. Costs for health states included drug acquisition costs and health 
care resource use (HRU) classified by MF risk status (high or intermediate-2) and 
leukemia. HRU estimates are based on patient level data (n= 88) from Auria Biobank, 
and utility values were based on a standard gamble study. Finnish health care payer 
perspective was employed. The time horizon in the base case was a lifetime with 3 % 
discounting for costs and outcomes. Results: Treatment with RUX produced 2.43 
incremental QALYs with the incremental cost of € 102,802 compared to BAT, resulting 
incremental cost-effectiveness ratio 42,367€ /QALY. Sensitivity analyses showed that 
the model was robust to changes in model inputs. The most impactful parameters 
were the disease management costs and the hazard ratio for OS. cOnclusiOns: 
The results suggest that the improvements in OS provided by RUX translate into 
long term gains in QALYs with reasonable incremental costs. The use of robust real-
life data from Auria Biobank is beneficial in managing uncertainty that relates to 
assumptions and data inputs of the model.
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Objectives: To assess the societal cost-effectiveness of manual therapy (MT) in 
comparison with physical therapy (PT) among Dutch sub-acute and chronic non-
specific neck pain patients. MethOds: An economic evaluation was conducted 
alongside a 52-week randomized controlled trial (RCT). In this RCT, 181 patients were 
randomized to the MT group (n= 90; mainly receiving mobilization) and PT group 
(n= 91; mainly receiving exercise therapy). Clinical outcomes included perceived 
recovery (yes/no), functional status (continuous and clinically relevant improvement 
- yes/no), and quality-adjusted life-years (QALYs). Societal costs were measured 
using self-reported questionnaires at three, 7, 13, 26, 39, and 52 weeks. Missing 
data were handled using multiple imputation. Bootstrapping techniques were used 
to assess the uncertainty of the results. Results: After 52 weeks, there were no 
significant between-group differences in clinical outcomes. During follow-up, inter-
vention costs (€ -32; 95%CI:-54 to -10) and healthcare costs (€ -126; 95%CI:-235 to 
-32) were significantly lower in the MT group than in the PT group, whereas unpaid 
productivity costs were significantly higher (€ 186; 95%CI:19 to 557). Societal costs 
did not significantly differ between groups (€ -96; 95%CI:-1975 to 2022). For QALYs 
and clinically relevant improvement in functional status, the maximum probability 
of MT being cost-effective in comparison with PT was low (≤ 0.54). For perceived 
recovery and continuous improvement in functional status, results showed that a 
large amount of money must be paid per additional unit of effect to reach a reason-
able probability of cost-effectiveness. cOnclusiOns: The findings indicate that 
MT was not cost-effective in comparison with PT in patients with sub-acute and 
chronic non-specific neck pain for perceived recovery, functional status, and QALYs.
trolled, multicenter clinical study in which patients have been treated with ex-
vivo expanded autologous human corneal epithelial cells containing stem cells. 
Symptoms like pain, photophobia and burning, together with visual impairment, 
contributed to assess quality of life associated with the condition, while Quality 
Adjusted Life Years (QALYs) have been used to compare the outcomes of the recent 
approved product with conservative management, in a comparable patient pool. 
The considered cost data have been obtained from Italian tariff nomenclature 
databases. Results: Patients treated with conservative management presented 
QALY values between 6.51 and 9.71, depending on LSCD severity, whereas treat-
ments with ATMP ensured to patients between 10.22 and 13.60 QALY, with a total 
utility gain between 3.71 and 4.60 QALYs (result being discounted by 3.5% yearly). 
As a result of this utility gain, the approved product would meet an ICER threshold 
of 40,000 € /QALY cost of around € 160,000 per treatment. cOnclusiOns: Offering 
long-term, potentially life-long, effectiveness after single treatment, ATMP analyzed 
delivers cost reduction in the long term management of LSCD, despite higher initial 
costs compared to conservative approach. The CEA of the product demonstrated a 
significant gain in terms of QALYs, amortizing the initial outlay for the treatment.
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Objectives: The aim of this study was to estimate the cost-effectiveness of lidocaine/
tetracaine patch versus lidocaine/prilocaine cream for topical anaesthesia before vas-
cular access. MethOds: A decision analytic model comparing lidocaine/tetracaine 
patch versus lidocaine/prilocaine cream for topical anaesthesia before vascular access 
was constructed based on the current clinical practice in Egypt and was derived 
from published sources. The clinical parameters were derived from a double-blind, 
randomized, paired study. The utility of the health states was derived using the avail-
able published data. Direct medical costs were obtained from the Ministry of health 
tariff in Egypt. No discounting was performed. Probabilistic sensitivity analysis (PSA) 
was conducted. Results: The total quality-adjusted life-years (QALYs) of Lidocaine/
Tetracaine patch was estimated to be 0.914147, whereas that of the lidocaine/prilo-
caine was estimated to be 0.826098 (with a net difference of 0.088049 QALYs). The 
total costs for Lidocaine/Tetracaine and lidocaine/prilocaine were EGP 93.19 and EGP 
60.00 respectively (with a net difference of 33.19 EGP). Thus the incremental cost-
effectiveness ratio (ICER) for Lidocaine/Tetracaine was EGP 376.95 /quality-adjusted 
life year. Results from PSA indicate that Lidocaine/Tetracaine had an 100% chance 
of being cost-effective at our EGP 70,000 per QALY threshold. cOnclusiOns: The 
present study concludes that Lidocaine/Tetracaine ( Heated Patch Delivery System) 
is cost effective option for topical anaesthesia before vascular access when compared 
with lidocaine/prilocaine (Cream) based on the threshold stated by world health 
organization (3xGDP/capita) for low and middle-income countries.
PSY60
an in SiliCo hEalth EConomiC modEl aPPliEd to CRYoPYRin aSSoCiatEd 
PERiodiC SYndRomES (CaPS): CoSt EffECtivEnESS of PREvEntion EffECtS 
of ultRa-oRPhan dRugS foR RaRE diSEaSES
Trieste L1, Della Casa Alberighi O2, Accame L2, Lorenzoni V1, Frenkel J3, Gattorno M2, 
Quartier P4, Martini A2, Turchetti G1
1Scuola Superiore Sant’Anna, Pisa, Italy, 2Institute Giannina Gaslini, Genova, Italy, 3University 
Medical Center Utrecht, Utrecht, The Netherlands, 4Assistance Publique-Hopitaux de ParisHopital 
Necker, Paris, France
Objectives: This three-year, international, multicentre, longitudinal, obser-
vational, cost-effectiveness study named RaDiCEA (RareDisease &Cost-
EffectivenessAnalysis) will assess the economic evaluation (cost of illness - COI 
and cost-effectiveness analisys - CEA) of innovative therapies (i.e., anti IL-1 
agents), quality of life (QoL) and effects of the prevention of otherwise irreversible 
central nervous system, eye, ear, kidney, and cartilage damages of different treat-
ment strategies for cryopyrin-associated periodic syndromes (CAPS) of adults and 
children. MethOds: A virtual time-cohort approach and a Markov model simu-
lating health states corresponding to different CAPS severity will be developed to 
assess the cost-effectiveness of either anti IL-1 agents or other than anti IL-1. Due 
to the lack of a CAPS-specific severity index/damage score, a linear combination 
of existing indexes and damage scores related to specific organs and systems will 
be used to rank patient’s health statu. Coefficients of the resulting function will be 
assigned following a top-down (Delphi) approach and an interim-ex post principal 
component analysis. The model quantifies resource utilization for patients’ care 
in the National Health Systems’ perspectives and a broader societal perspective. 
QoL will be evaluated using EQ-5D questionnaires. Robustness of outcomes wil 
be tested through univariate and probabilistic sensitivity analyses. Results: The 
RaDiCEA project will assess the long-term effectiveness of different potentially 
life-long treatment strategies and COI, while exploring the feasibility of a new 
CEA model to be generated from a rare disease (CAPS) observational study. The 
economic outcomes will be given as the number of years spent in each health 
state, the related yearly costs and QoL. cOnclusiOns: The importance and nov-
elty of the model is twofold: i) in its application, adopting the cost-effectiveness 
approach for assessing the impact of CAPS therapies, and ii) in the methods, 
extending the analyses of the impact of CAPS therapies in reducing the speed of 
disease progression.
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